歌禮制藥-B(01672.HK):IIb期試驗中期結果顯示經皮下注射單克隆抗體ASC22治療後,在慢性乙型肝炎患者中觀察到持續的乙肝表面抗原消失
格隆匯11月9日丨歌禮制藥-B(01672.HK)發佈公吿,根據其皮下注射PD-L1抗體ASC22(恩沃利單抗)IIb期臨牀試驗(臨牀試驗編號:NCT04465890)的44位患者的中期結果,在基線乙肝表面抗原≤500 IU/mL的患者中可以觀察到持續的乙肝表面抗原消失。該結果形成的摘要被2021年美國肝病研究協會(AASLD)年會(The Liver Meeting® 2021)選為最新研究摘要並作口頭報吿。根據美國肝病研究協會(AASLD)年會的選取標準,最新研究摘要必須是具有高度科學重要性和影響力的研究成果。
該IIb期試驗是一項隨機、單盲、安慰劑對照、多中心的中國臨牀試驗,用於評估在慢性乙型肝炎患者中24周每2周1次1 mg/kg、2.5 mg/kg ASC22或安慰劑聯合核苷(酸)類似物的安全性和有效性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.